Patients can expect the same trusted support from Sanofi Genzyme.
Sanofi Genzyme’s support services represent our more than 35-year commitment to supporting the rare disease community. We are dedicated to our mission and will continue to provide the comprehensive support services that patients have relied on for years.
TRANSITIONING TO NEXVIAZYME CAN BE A SEAMLESS PROCESS
Patients can receive NEXVIAZYME at their regular infusion center
Co-pay and financial assistance are available for eligible patients, similar to alglucosidase alfa
Your patient may be eligible for the QuickStart Program
QuickStart provides NEXVIAZYME at no cost to eligible, commercially insured patients in the event of coverage delays or denials. Examples include but are not limited to:
- Delays in prior insurance authorizations
- Waiting for exceptions and appeal determinations
- Reinitiation of prior insurance authorizations due to transitions to new health insurers
Sanofi Genzyme may be able to help your patients start treatment
Your patients may be eligible for the CareConnectPSS® QuickStart Program. Patients can receive NEXVIAZYME at no charge while their insurance authorization is being reviewed. Certain eligibility restrictions apply.
- The patient’s healthcare provider must send the application for QuickStart (as indicated on the enrollment form)
- Once coverage has been obtained, the CareConnectPSS® QuickStart Program will transition the patient to the referring specialty pharmacy for commercial product
For more information, please call 1-800-745-4447, option 3, Monday through Friday, 8:00 am-6:00 pm ET for more information
Eligible patients may receive up to 4 infusions of NEXVIAZYME; in certain circumstances, eligibility may
QuickStart does not interfere with the referring specialty pharmacy’s ability to fulfill commercial product.
Check to see if your patient is eligible for QuickStart.
NEXVIAZYME CO-PAY PROGRAM
Sanofi Genzyme also offers co-pay assistance and charitable access programs for
The Co-Pay Assistance Program helps individuals in the United States who are prescribed NEXVIAZYME pay for their eligible out-of-pocket drug and infusion-related (mixing and administration of the drug as well as infusion supplies such as saline, IV tubing, etc.) expenses, including co-pays, co-insurance, and deductibles.
To participate in this program your patients must complete an enrollment application. Once enrolled, Sanofi Genzyme will cover 100% of their eligible out-of-pocket NEXVIAZYME drug costs, up to the program maximum.
The Co-Pay Program does not cover prescriptions eligible to be reimbursed, in whole or in part, by a state
or federal health care program, including but not limited to Medicare, Medicare Advantage Plans (Example: FreedomBlue offered through BlueCross Blue Shield), Medicare Part D, Medicaid, Medigap, Veterans Affairs,
Department of Defense, or TRICARE.
In accordance with State law, the Program does not reimburse infusion-related charges for commercially insured patients residing in Massachusetts or Rhode Island. (Charitable Access Program patients residing in these states are eligible to receive assistance for infusion-related charges while they are receiving charitable drug.)
No claim for reimbursement of any out-of-pocket expenses covered by the Co-Pay Program may be submitted to any third-party payer, whether public or private. The Co-Pay Program is available only in the United States and cannot be combined with any other rebate/coupon, free trial, or similar offer. Co-Pay benefits are not transferrable.
Sanofi Genzyme reserves the right to rescind, revoke, modify, or amend this program without notice.
Patient Assistance Program
Qualified individuals with Pompe disease whose physicians have recommended treatment with NEXVIAZYME may be eligible for the Patient Assistance Program. Learn more about the CareConnectPSS® Patient Assistance Program and download the application form.
Explore a List of Helpful Organizations & Educational Resources
There are numerous resources available to both healthcare providers and their patients to help contribute to their understanding of Pompe disease.
Professional and patient organizations can help educate and bring together those in the Pompe community, and Sanofi Genzyme offers years of expertise and resources on treating, managing, and living with the disease. Sanofi Genzyme is committed to providing practitioners with information and access to resources that continue to help improve standards of care for patients with Pompe disease.
The Pompe Registry
This ongoing, observational database sponsored by Sanofi Genzyme tracks the natural history and outcomes of patients with Pompe disease. All patients with Pompe disease are eligible for enrollment irrespective of their treatment status, and all physicians managing patients with Pompe disease are encouraged to learn about the Pompe Registry.